Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Harrow Health, Inc. 8.625% Senior Notes due 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 News
No news available
Harrow Health, Inc. 8.625% Senior Notes due 2026 Quantitative Score
About Harrow Health, Inc. 8.625% Senior Notes due 2026
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Harrow Health, Inc. 8.625% Senior Notes due 2026 Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Harrow Health, Inc. 8.625% Senior Notes due 2026 Financials
Table Compare
Compare HROWL metrics with: | |||
|---|---|---|---|
Earnings & Growth | HROWL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | HROWL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | HROWL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | HROWL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Harrow Health, Inc. 8.625% Senior Notes due 2026 Income
Harrow Health, Inc. 8.625% Senior Notes due 2026 Balance Sheet
Harrow Health, Inc. 8.625% Senior Notes due 2026 Cash Flow
Harrow Health, Inc. 8.625% Senior Notes due 2026 Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Harrow Health, Inc. 8.625% Senior Notes due 2026 Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 2.1562 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-07-31 | 0.53906 | Quarterly |
| 2025-04-30 | 0.53906 | Quarterly |
| 2025-01-31 | 0.53906 | Quarterly |
| 2024-10-31 | 0.53906 | Quarterly |
| 2024-07-31 | 0.53906 | Quarterly |
Historical Market Cap
Shares Outstanding
Harrow Health, Inc. 8.625% Senior Notes due 2026 Insider Trades
| Date | 16 Nov |
| Name | BAUM MARK L |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 7500 |
| Date | 15 Nov |
| Name | Opaleye Management Inc. |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 25000 |
| Date | 10 Nov |
| Name | SAHAREK JOHN P. |
| Role | Chief Commercial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 20000 |
| Date | 10 Nov |
| Name | SAHAREK JOHN P. |
| Role | Chief Commercial Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 9778 |
| Date | 10 Nov |
| Name | SAHAREK JOHN P. |
| Role | Chief Commercial Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 20000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 16 Nov | BAUM MARK L | Chief Executive Officer | Acquired | P-Purchase | 7500 |
| 15 Nov | Opaleye Management Inc. | 10 percent owner | Acquired | P-Purchase | 25000 |
| 10 Nov | SAHAREK JOHN P. | Chief Commercial Officer | Acquired | M-Exempt | 20000 |
| 10 Nov | SAHAREK JOHN P. | Chief Commercial Officer | Disposed | F-InKind | 9778 |
| 10 Nov | SAHAREK JOHN P. | Chief Commercial Officer | Disposed | M-Exempt | 20000 |